Andreas Skolarikos1, Michael Straub2, Thomas Knoll3, Kemal Sarica4, Christian Seitz5, Ales Petřík6, Christian Türk7. 1. Second Department of Urology, Sismanoglio Hospital, Athens Medical School, Athens, Greece. Electronic address: andskol@yahoo.com. 2. Department of Urology, Technical University Munich, Munich, Germany. 3. Department of Urology, Sindelfingen-Boeblingen Medical Center, University of Tübingen, Sindelfingen, Germany. 4. Department of Urology, Dr Lutfi Kırdar Research and Teaching Hospital, Istanbul, Turkey. 5. Department of Urology, Medical University Vienna, Austria. 6. Department of Urology, Region Hospital, České Budějovice, Czech Republic; Department of Urology, Charles University, 1st Faculty of Medicine, Prague, Czech Republic. 7. Department of Urology, Rudolfstiftung Hospital, Vienna, Austria.
Abstract
CONTEXT: An optimum metabolic evaluation strategy for urinary stone patients has not been clearly defined. OBJECTIVE: To evaluate the optimum strategy for metabolic stone evaluation and management to prevent recurrent urinary stones. EVIDENCE ACQUISITION: Several databases were searched to identify studies on the metabolic evaluation and prevention of stone recurrence in urolithiasis patients. Special interest was given to the level of evidence in the existing literature. EVIDENCE SYNTHESIS: Reliable stone analysis and basic metabolic evaluation are highly recommended in all patients after stone passage (grade A). Every patient should be assigned to a low- or high-risk group for stone formation. It is highly recommended that low-risk stone formers follow general fluid and nutritional intake guidelines, as well as lifestyle-related preventative measures to reduce stone recurrences (grade A). High-risk stone formers should undergo specific metabolic evaluation with 24-h urine collection (grade A). More specifically, there is strong evidence to recommend pharmacological treatment of calcium oxalate stones in patients with specific abnormalities in urine composition (grades A and B). Treatment of calcium phosphate stones using thiazides is only highly recommended when hypercalciuria is present (grade A). In the presence of renal tubular acidosis (RTA), potassium citrate and/or thiazide are highly recommended based on the relative urinary risk factor (grade A or B). Recommendations for therapeutic measures for the remaining stone types are based on low evidence (grade C or B following panel consensus). Diagnostic and therapeutic algorithms are presented for all stone types based on the best level of existing evidence. CONCLUSION: Metabolic stone evaluation is highly recommended to prevent stone recurrences. PATIENT SUMMARY: In this report, we looked at how patients with urolithiasis should be evaluated and treated in order to prevent new stone formation. Stone type determination and specific blood and urine analysis are needed to guide patient treatment.
CONTEXT: An optimum metabolic evaluation strategy for urinary stonepatients has not been clearly defined. OBJECTIVE: To evaluate the optimum strategy for metabolic stone evaluation and management to prevent recurrent urinary stones. EVIDENCE ACQUISITION: Several databases were searched to identify studies on the metabolic evaluation and prevention of stone recurrence in urolithiasispatients. Special interest was given to the level of evidence in the existing literature. EVIDENCE SYNTHESIS: Reliable stone analysis and basic metabolic evaluation are highly recommended in all patients after stone passage (grade A). Every patient should be assigned to a low- or high-risk group for stone formation. It is highly recommended that low-risk stone formers follow general fluid and nutritional intake guidelines, as well as lifestyle-related preventative measures to reduce stone recurrences (grade A). High-risk stone formers should undergo specific metabolic evaluation with 24-h urine collection (grade A). More specifically, there is strong evidence to recommend pharmacological treatment of calcium oxalate stones in patients with specific abnormalities in urine composition (grades A and B). Treatment of calcium phosphate stones using thiazides is only highly recommended when hypercalciuria is present (grade A). In the presence of renal tubular acidosis (RTA), potassium citrate and/or thiazide are highly recommended based on the relative urinary risk factor (grade A or B). Recommendations for therapeutic measures for the remaining stone types are based on low evidence (grade C or B following panel consensus). Diagnostic and therapeutic algorithms are presented for all stone types based on the best level of existing evidence. CONCLUSION: Metabolic stone evaluation is highly recommended to prevent stone recurrences. PATIENT SUMMARY: In this report, we looked at how patients with urolithiasis should be evaluated and treated in order to prevent new stone formation. Stone type determination and specific blood and urine analysis are needed to guide patient treatment.
Keywords:
European Association of Urology; Guidelines; Lithiasis; Medical treatment; Metabolic evaluation; Recurrence and conservative treatment; Stone; Urinary
Authors: Pietro Manuel Ferraro; Miguel Ángel Arrabal-Polo; Giovambattista Capasso; Emanuele Croppi; Adamasco Cupisti; Thomas Ernandez; Daniel G Fuster; Juan Antonio Galan; Felix Grases; Ewout J Hoorn; Felix Knauf; Emmanuel Letavernier; Nilufar Mohebbi; Shabbir Moochhala; Kremena Petkova; Agnieszka Pozdzik; John Sayer; Christian Seitz; Pasquale Strazzullo; Alberto Trinchieri; Giuseppe Vezzoli; Corrado Vitale; Liffert Vogt; Robert J Unwin; Olivier Bonny; Giovanni Gambaro Journal: Urolithiasis Date: 2019-03-08 Impact factor: 3.436
Authors: Ron Gilad; James C Williams; Kalba D Usman; Ronen Holland; Shay Golan; Ruth Tor; David Lifshitz Journal: J Nephrol Date: 2016-03-08 Impact factor: 3.902
Authors: Saeed R Khan; Margaret S Pearle; William G Robertson; Giovanni Gambaro; Benjamin K Canales; Steeve Doizi; Olivier Traxer; Hans-Göran Tiselius Journal: Nat Rev Dis Primers Date: 2016-02-25 Impact factor: 52.329